World-class treatment planning programs, developed for both the Xoft controller and general intraoperative radiation therapy (IORT) with the Xoft System
For early-stage breast cancer patients, IORT with the Xoft System allows appropriately selected patients to potentially replace six to eight weeks of post-operative external beam radiation therapy (EBRT) with a single-fraction of radiation that can last as little as eight minutes. It uses a miniaturized x-ray source to deliver one precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body.
“We may be approaching a significant paradigm shift in the way clinicians treat cancer, especially with a likely decision on the Radiation Oncology Alternative Payment Model (RO-APM) anticipated in the months ahead,” said Michael Klein, Chairman and CEO of iCAD. “As a single-fraction treatment therapy for early-stage breast cancer, Xoft IORT is a viable and verified treatment option that appears well-aligned with the core elements of the proposed model. The Company is poised to transform patient experiences and outcomes in the years ahead as a platform technology across multiple cancer indications.”
A growing body of evidence continues to support the Xoft System across multiple cancer types. At ASTRO, findings from a Vanderbilt University School of Medicine study supporting Xoft IORT for early-stage breast cancer will be presented on Sunday, September 15 at 1:15 pm CT in the Breast Cancer Track.
iCAD will also host “An Evening of eBx” cocktail reception on Monday, September 16, at the Marriott Marquis Chicago at 6 pm CT. The event will feature clinical experts who will discuss the latest research and emerging applications for eBx and IORT with the Xoft System.
The Xoft System is FDA-cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, nonmelanoma skin cancer, and gynecological cancers.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.
Back to HCB News
